MILWAUKEE, July 21, 2026
Estrigenix Therapeutics announced the first closing of its $2 million Series Seed financing, led by Talents Fund I, to accelerate development of its proprietary selective estrogen receptor-beta (ERβ) platform targeting women’s health and neurodegenerative diseases. The investment will fund lead optimization, completion of the company’s translational preclinical development package, and preparation for IND-enabling studies, positioning its lead candidates for future clinical development. The financing follows several strategic milestones, including completion of Estrigenix’s exclusive intellectual property license, the appointment of Victoria Zellmer as Chief Executive Officer, continued advancement of its preclinical research program, and growing interest from pharmaceutical companies regarding future partnership opportunities around its lead therapeutic candidate.
Seed Financing Accelerates ERβ Platform Development
The newly secured funding will enable Estrigenix to further advance its non-steroidal selective ERβ platform, which is designed to target underlying disease biology rather than simply treating symptoms associated with declining estrogen levels. According to the company, the platform has the potential to address multiple women’s health disorders and neurodegenerative diseases through a shared biological mechanism involving selective activation of the estrogen receptor-beta pathway. Capital from the financing will support optimization of lead compounds, completion of translational preclinical studies, and generation of data necessary to support future IND-enabling development, creating a foundation for eventual clinical evaluation.
Differentiated Platform Targets Broad Disease Opportunities
Unlike conventional hormone replacement approaches, Estrigenix’s selective ERβ platform seeks to provide therapeutic benefits without relying on steroid hormone therapies. The company believes its differentiated scientific approach could support development across a range of indications linked to estrogen signaling while potentially offering improved safety and broader clinical utility. Recent scientific progress has also generated increasing interest from pharmaceutical companies evaluating future collaboration opportunities surrounding Estrigenix’s lead candidate. Company leadership noted that the financing validates years of research and enables continued expansion of a platform designed to address significant unmet medical needs across multiple therapeutic areas.
Advertisement
Company Positions Pipeline for Clinical Advancement
Chief Executive Officer Victoria Zellmer described the financing as an important milestone that enables Estrigenix to transition from platform development toward clinical-stage execution while expanding future pipeline opportunities. Talents Fund I, the lead investor, highlighted the growing scientific interest in ERβ biology as an emerging therapeutic strategy for women’s health and neurological disorders. With its intellectual property secured, leadership team established, and preclinical programs progressing, Estrigenix plans to advance its lead candidates toward IND-enabling studies, laying the groundwork for future clinical trials and potential strategic partnerships as it expands its precision medicine pipeline.
Source: Estrigenix Therapeutics press release
